Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1

Leukemia. 2015 Sep;29(9):1939-42. doi: 10.1038/leu.2015.42. Epub 2015 Feb 13.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / chemistry
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Mutation*
  • Protein Interaction Domains and Motifs / genetics*
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl